

Welcome to Penzberg

One of Europe's largest biotech facilities



The Roche Group's largest biotech facility

The Penzberg site

Profile

Role

Diagnostics

Pharmaceuticals

Future

Where it all began ...
The Penzberg site in 1957



Where it all began ...

The Penzberg site in 1957 and 2004



The Penzberg site today


- **Founded:** 1972 (Boehringer Mannheim)
- **Area:** 310,000 m²
- **Employees:** 3,459 (Dec. 03)
- **Invested capital:** 870 Mill. € (Dec. 03)



The Penzberg site

Headcount


Number of employees



*until 2000 incl. Tutzing


The Penzberg site

Employee qualifications



The Penzberg site


Average age



* incl. Tutzing until 2000

The Penzberg site

Capital expenditure



The Roche Group's largest biotech facility

The Penzberg site

Profile

Role

Diagnostics

Pharmaceuticals

Future

Penzberg's Role

Penzberg is the only location worldwide where both divisions have on-site research, development and production facilities

Diagnostics *(approx. 2,600 employees)*

R & D

Production

Pharma *(approx. 710 employees)*


Research

Production

Penzberg's Role

Biotechnology

- One of Europe's largest Biotech facilities
- Largest Biotech site in the Roche Group
- Supplies products for Diagnostics and Pharmaceuticals
- Most Diagnostics' products are biotechnology based
- Produces 4 important biopharmaceuticals



The Roche Group's largest biotech facility

The Penzberg site

Profile

Role

Diagnostics

Pharmaceuticals

Future

Roche Diagnostics *Product portfolio*



Life Science Research | in-vitro diagnostics market

Research | Professionals | Consumers

Applied Science



LightCycler



Cobas Ampliprep

Molecular Diagnostics



Omni S

Centralized Diagnostics

Modular Analytics E 170



Near Patient Testing


Diabetes Care

Accu-Chek Go



Roche Diagnostics

Regional headquarters and R&D centres



Penzberg's Role

Diagnostics

- *R&D centre*
for reagents in
 - clinical chemistry
 - immunology
- *Centre of Excellence*
for active ingredients
(R&D and Production)



Biotechnology in Penzberg

Diagnostics

Diagnostic reagents and systems

- Research reagents (e.g. restriction enzymes)
- Industrial products (e.g. catalase)
- Enzyme tests (e.g. cholesterol)
- Immune tests (e.g. tumor markers)
- Nucleic acid diagnosis (e.g. HIV)



Diabetes: Blood sugar measurement
Enzymes e.g. glucose oxidase

The Roche Group's largest biotech facility

The Penzberg site

Profile

Role

Diagnostics

Pharmaceuticals

Future

Penzberg's Role

Pharmaceuticals

Diagnostics *(approx. 2,600 employees)*

R & D

Production

Pharma *(approx. 710 employees)*

Research

Production



The Roche Group


A global leader in biopharmaceuticals

Roche Group 1st half 2004	Sales in CHF m	Change H1/2004 vs. H1/2003
MabThera/Rituxan	1624	+ 31%
NeoRecormon/Epogin	1020	+ 3%
Pegasys/Copegus	783	+ 142%
Cellcept	719	+ 19%
Herceptin	674	+ 26%
Rocephin	684	+ 0%
Xenical	311	+ 0%
Xeloda	243	- 11%
Nutropin/Protropin	225	+ 10%
Kytril	220	+ 13%

green: Biopharmaceuticals


Penzberg's Role *Pharmaceuticals*

- One of 4 Roche's pharmaceutical research centres
- Largest research location for oncology
- *Centre of Excellence* for pharmaceutical active ingredients



Pharma Biologicals

Penzberg



Biologicals Tech.Dev.
and Manufacturing

Biologicals Technical Development


Biologicals R&D

New Biologicals
Manufacturing

Biologicals
Manufacturing



Roche global R&D centres



Biotechnology production in Penzberg

Pharmaceuticals

Active ingredients for drugs:

- Erythropoietin / Neorecormon[®]
- Recombinant plasminogen activator Rapilysin[®] / reteplase
- Trastuzumab / Herceptin[®]
- Peg-Interferone-alpha 2a/ Pegasys[®]
- Over 200 antibodies for diagnostic tests
- Active ingredients for clinical studies

Approved by FDA and EMEA



Pharma biotech production

The Roche Group's largest biotech facility

Site Penzberg

Profile

Role

Diagnostics

Pharmaceuticals

Future

The Penzberg site

Biotechnology projects

Building 354

EPO (Erythropoietin)

Investment: €182 m

Completion: July 2005



The Penzberg site

Biotechnology projects

Building 345

Monoclonal antibodies for
Diagnostics

Investment: € 31.4 m

Completion: March 2006



The Penzberg site

Biotechnology projects

Building 361/362 Bio

Herceptin

Investment: € 290 m

Completion: December 07

